CClinicalTrials.gg
CompletedNCT03307967Updated Feb 15, 2024Results posted

Pilot of Pragmatic SBIRT Study

An interventional study of SBIRT-PM in Substance Use Disorders and Pain, sponsored by Yale University. Completed at 2 sites in United States. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2024-02-15.

Sponsored by Yale University · Not applicable, Interventional, and Screening

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years to 100 Years
Sex
All
01

Study summary

Veterans seeking compensation for musculoskeletal (MSD) conditions often develop chronic pain and are at high risk for substance misuse. This study is designed to pilot test the Screening, Brief Intervention and Referral to Treatment for Pain Management (SBIRT-PM) intervention. SBIRT-PM is designed to reduce pain and reduce risky substance use among veterans applying for VA Benefits for a musculoskeletal condition, in part by helping Veterans get connected to comprehensive pain treatment. This pilot will involve a 2-year period to arrange for SBIRT Counselors at a single site to counsel Veterans throughout New England by phone with SBIRT-PM to test the acceptability and feasibility of the intervention.

Read the detailed description

In 2015 alone, 97,223 new Veterans under age 35 began receiving compensation for injuries related to their military service. In total, there are 559,999 post-9/11 Veterans being compensated for back or neck conditions, and a partially overlapping 596,250 for limitation of flexion in joints. Veterans seeking compensation for musculoskeletal conditions often develop chronic pain and are at high risk for substance misuse. Early intervention is needed to arrest worsening pain and risky substance use, particularly among post-9/11 Veterans for whom engagement in non-pharmacological pain treatment has the potential to improve their overall quality of life and spare them the complications of opioid treatments. The service-connection application is an ideal point-of-contact for initiating early intervention treatments for these at-risk Veterans.

This study is designed to pilot test the Screening, Brief Intervention and Referral to Treatment for Pain Management (SBIRT-PM) intervention. SBIRT-PM is designed to reduce pain and reduce risky substance use among veterans applying for VA Benefits for a musculoskeletal condition, in part by helping Veterans get connected to comprehensive pain treatment. This pilot will involve a 2-year period to arrange for SBIRT Counselors at a single site to counsel Veterans throughout New England by phone with SBIRT-PM to test the acceptability and feasibility of the intervention.

During the two-years pilot trial, the team will prepare SBIRT-PM for implementation by establishing communication (Relational Coordination is the theoretical framework) between the "hub" where the SBIRT-PM clinician is sited and the "spoke" sites, establishing study-related procedures, and piloting the intervention at each of the eight VA medical centers in New England.

02

Conditions studied

  • Substance Use Disorders
  • Pain
03

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Post-9/11 Veteran applying for MSD-related compensation, as ascertained from filed claim,
  • Reports pain ≥4 on the pain Numerical Rating Scale (threshold for moderately severe pain);
  • Availability of a landline or cellular telephone for SBIRT-PM.

Exclusion criteria

Exclusion Criteria:

  • Reports inability to participate during the study enrollment call
  • Received three or more non-pharmacological pain treatment modalities (as previously categorized within the last 12 weeks from VA.
04

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    SBIRT-PM

    Screening, Brief Intervention and Referral to Treatment for Pain Management (SBIRT-PM) was developed to promote engagement in multi-modal non-pharmacological pain management among compensation-seeking Veterans with chronic pain. In SBIRT-PM, a clinician meets with the Veteran after the compensation examination to address the presenting MSD complaint. The clinician addresses Veterans' motivation for multi-modal pain care, and explains how pain can be managed using a variety of non-pharmacological pain management services. The clinician spells out how those services can be accessed at VA. Using permissive language about how pain is commonly self-medicated with substances, the clinician transitions to inquiries about use of prescription and non-prescription substances. The clinician then attempts to motivate Veterans to change their behavior if they are misusing substances. Thus, SBIRT-PM addresses the Veteran's presenting pain complaint first and nascent substance use subsequently.

    Behavioral: SBIRT-PM

Interventions

  • BehavioralSBIRT-PM

    SBIRT-PM involves an initial telephone-delivered session followed by up to three calls to Veterans in a 12-week period to support Veteran engagement in multi-modal non-pharmacological pain care and to motivate those who misuse substances to change this problematic behavior. SBIRT-PM also includes coordination between the SBIRT-PM clinicians and the PACT nurse case manager after the initial session to support these patient outcomes.

05

What researchers measure

Primary outcomes

  1. Non-Pharm Pain Treatment Modalities Received

    A self-reported measure developed by the Pain Management Collaboaratory (PMC3). Questionnaire asks about the use of 13 different non-pharmacological pain treatments over the past 3 months. Below we present the mean number of non-pharmacological pain treatments received at baseline and then at week 12.

    Time frame: Baseline, Week 12

  2. Substance Use

    Measured by the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST). This self-reported assessment asks about the use of 10 classes of substances used over the preceding 3 months. In the below table, we present the number of participants that endorsed having used the indicated substance at baseline and week 12.

    Time frame: Baseline, week 12

  3. Change in Pain Severity

    Measured by the pain severity subscale of the Brief Pain Inventory (BPI). The BPI is a validated instrument to assess chronic non-cancer pain. The pain severity subscale consists of 4 items (worst pain, least pain, average pain, current pain) rated in the past 24 hours on a 0-10 scale- higher scores indicate higher pain severity. The four items are averaged to get a score. Below we present the mean, within-person change in pain severity from baseline to week 12. Minimally clinically important difference would be a 30% reduction in pain severity.

    Time frame: Baseline to 12 weeks

  4. Change in Pain Interference

    Measured by the pain interference subscale of the Brief Pain Inventory (BPI). The BPI is a validated instrument to assess chronic non-cancer pain. The pain interference subscale consists of 7 items rated in the past 24 hours on a 0-10 scale- higher scores indicate higher interference from pain. The 7 items are averaged to get a score. Below we present the mean, within-person change in pain intensity from baseline to week 12. Minimally clinically important difference would be a 1 point reduction in pain intensity.

    Time frame: Baseline to 12 weeks

06

Results

Posted May 16, 2022

Participant flow

Veterans in catchment area of New England VA Medical Centers applying for C\&P disability benefits for a back, neck, knee, or shoulder condition

Participant flow — Overall Study
MilestoneSBIRT-PM
Started40
Completed36
Not completed4
Withdrew: Lost to follow-up4

Outcome measures

PrimaryNon-Pharm Pain Treatment Modalities Received

A self-reported measure developed by the Pain Management Collaboaratory (PMC3). Questionnaire asks about the use of 13 different non-pharmacological pain treatments over the past 3 months. Below we present the mean number of non-pharmacological pain treatments received at baseline and then at week 12.

Time frame:
Baseline, Week 12
Reported as:
Mean · non-pharm pain treatments
Non-Pharm Pain Treatment Modalities Received
non-pharm pain treatmentsSBIRT-PM
# non-pharm pain treatments at Baseline.93 ± 1.0
# non-pharm pain treatments at week 121.3 ± 1.3
PrimarySubstance Use

Measured by the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST). This self-reported assessment asks about the use of 10 classes of substances used over the preceding 3 months. In the below table, we present the number of participants that endorsed having used the indicated substance at baseline and week 12.

Time frame:
Baseline, week 12
Reported as:
Number · participants
Substance Use
participantsSBIRT-PM
Baseline : Alcohol13
Baseline : Nicotine16
Baseline : Other Drugs7
Baseline : Alcohol or drugs27
Week 12 : Alcohol6
Week 12 : Nicotine15
Week 12 : Other Drugs8
Week 12 : Alcohol or drugs22
PrimaryChange in Pain Severity

Measured by the pain severity subscale of the Brief Pain Inventory (BPI). The BPI is a validated instrument to assess chronic non-cancer pain. The pain severity subscale consists of 4 items (worst pain, least pain, average pain, current pain) rated in the past 24 hours on a 0-10 scale- higher scores indicate higher pain severity. The four items are averaged to get a score. Below we present the mean, within-person change in pain severity from baseline to week 12. Minimally clinically important difference would be a 30% reduction in pain severity.

Time frame:
Baseline to 12 weeks
Reported as:
Mean · within-person change in score on a scale
Change in Pain Severity
within-person change in score on a scaleSBIRT-PM
Change in Pain Severity-.41 ± 1.3
Statistical analysis
  • SBIRT-PM · Wilcoxon (Mann-Whitney) · p = .07Wilcoxon Signed Rank Sum
PrimaryChange in Pain Interference

Measured by the pain interference subscale of the Brief Pain Inventory (BPI). The BPI is a validated instrument to assess chronic non-cancer pain. The pain interference subscale consists of 7 items rated in the past 24 hours on a 0-10 scale- higher scores indicate higher interference from pain. The 7 items are averaged to get a score. Below we present the mean, within-person change in pain intensity from baseline to week 12. Minimally clinically important difference would be a 1 point reduction in pain intensity.

Time frame:
Baseline to 12 weeks
Reported as:
Mean · within-person change on a scale
Change in Pain Interference
within-person change on a scaleSBIRT-PM
Change in Pain Interference.08 ± 1.6
Statistical analysis
  • SBIRT-PM · Wilcoxon (Mann-Whitney) · p = .98Wilcoxon Signed Rank Sum Test

Adverse events

Collected over 12 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SBIRT-PM0/40 (0%)0/40 (0%)8/40 (20%)
Most frequent other events
Most frequent other events
EventSBIRT-PM
Suicidal ideationPsychiatric disorders8/40

Baseline characteristics

Age, Continuous
Age, Continuous(years)SBIRT-PM
Mean40.2 (20 to 70)
Sex: Female, Male
Sex: Female, Male(Participants)SBIRT-PM
Female6
Male34
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)SBIRT-PM
White30
Black3
Other5
Unknown2
Hispanic6
Region of Enrollment
Region of Enrollment(participants)SBIRT-PM
United States40
Military Branch
Military Branch(Participants)SBIRT-PM
Army18
Marines5
Navy7
Airforce5
Coast Guard2
Army/Airforce2
Army/Marines1
07

Study locations

2 sites
  • Yale University
    New Haven, Connecticut 06520, United States
  • VA Connecticut Healthcare System (VACHS)
    West Haven, Connecticut 06516, United States
08

References and documents

Publications

  • Sellinger JJ, Martino S, Lazar C, Mattocks K, Rando K, Serowik K, Ablondi K, Fenton B, Gilstad-Hayden K, Brummett B, Holtzheimer PE, Higgins D, Reznik TE, Semiatin AM, Stapley T, Ngo T, Rosen MI. The acceptability and feasibility of screening, brief intervention, and referral to treatment for pain management among new England veterans with chronic pain: A pilot study. Pain Pract. 2022 Jan;22(1):28-38. doi: 10.1111/papr.13023. Epub 2021 Jun 26. PubMed 33934499 ↗
  • Rosen MI, Martino S, Sellinger J, Lazar CM, Fenton BT, Mattocks K. Access to Pain Care From Compensation Clinics: A Relational Coordination Perspective. Fed Pract. 2020 Jul;37(7):336-342. PubMed 32908339 ↗

Study documents

  • Protocol and statistical analysis plan · Mar 16, 2022
  • Informed consent form · May 12, 2020

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

09

Registry details

Key details

Study ID
NCT03307967
Lead sponsor
Yale University
Collaborators
National Center for Complementary and Integrative Health (NCCIH), National Institute on Drug Abuse (NIDA), US Department of Veterans Affairs
Responsible party
Sponsor
First posted
Oct 12, 2017
Start date
Jan 15, 2019
Primary completion
Jun 17, 2019
Completion
Jun 17, 2019
Results posted
May 16, 2022
Last update
Feb 15, 2024

Study contacts

Marc Rosen, MD
principal investigator · Yale University/ VA Connecticut Healthcare System
Steve Martino, PhD
principal investigator · Yale University/ VA Connecticut Healthcare System

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion